Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 9Recruiting 7Terminated 3Unknown 1Enrolling by invitation 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Parkinsonian Disorders 1Neoplasms 1Glioma 1

Interventions

Cisplatin 9Standard of Care 6Educational Status 6Nivolumab 5Interviews as Topic 5Carboplatin 5Radiotherapy 4Paclitaxel 4Oxaliplatin 4Dexamethasone 4pembrolizumab 3camrelizumab 3Practice Guidelines as Topic 3Patient Navigation 3Methods 3Magnetic Resonance Spectroscopy 3Magnetic Resonance Imaging 3Lenalidomide 3Fluorouracil 3Fluorodeoxyglucose F18 3Exercise 3Early Intervention, Educational 3Drug Therapy 3Cytarabine 3130-nm albumin-bound paclitaxel 3venetoclax 2toripalimab 2tislelizumab 2sacituzumab govitecan 2lenvatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Enrolling by invitation × Interventional × fluorodopa F 18 × Clear all
NCT07542158 2026-04-21

Ultralow Dose PET Imaging of 18F-FDOPA

Nuclear Imaging Institute

Phase 2 Enrolling by invitation
200 enrolled
CNS

Glioma, Neoplasms, Parkinsonian Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡